The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study
Por:
van Straalen, KR, Tzellos, T, Guillem, P, Benhadou, F, Cuenca-Barrales, C, Daxhelet, M, Daoud, M, Efthymiou, O, Giamarellos-Bourboulis, EJ, Jemec, GBE, Katoulis, AC, Koenig, A, Lazaridou, E, Marzano, AV, Matusiak, L, Molina-Leyva, A, Moltrasio, C, Pinter, A, Potenza, C, Romani, J, Saunte, DM, Skroza, N, Stergianou, D, Szepietowski, J, Trigoni, A, Vilarrasa, E, van der Zee, HH
Publicada:
1 ago 2021
Ahead of Print:
1 jul 2021
Resumen:
Background: Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes.
Objective: To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin. Methods: A prospective, international cohort study performed between October 2018 and August 2019.
Results: In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain.
Limitations: Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline.
Conclusion: This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.
Filiaciones:
van Straalen, KR:
Univ Med Ctr Rotterdam, Dept Dermatol, Erasmus MC, Rotterdam, Netherlands
Tzellos, T:
Nordland Hosp Trust, Dept Dermatol, Bod, Bodo, Norway
Guillem, P:
Clin Val Ouest, Dept Surg, Paris, France
ResoVerneuil, Paris, France
Grp Rech Proctol Soc Natl Francaise ColoProctol, Paris, France
Benhadou, F:
Univ Libre Bruxelles, Erasme Hosp, Dept Dermatol, Brussels, Belgium
Cuenca-Barrales, C:
Hosp Univ Virgen Nieves, Dept Dermatol, Granada, Spain
TECe19 Clin & Translat Dermatol Invest Grp Inst I, Granada, Spain
Daxhelet, M:
Univ Libre Bruxelles, Erasme Hosp, Dept Dermatol, Brussels, Belgium
Daoud, M:
Natl & Kapodistrian Univ Athens, Attikon Gen Univ Hosp, Med Sch, Dept Dermatol & Venereol 2, Athens, Greece
Efthymiou, O:
Natl & Kapodistrian Univ Athens, Med Sch, Dept Internal Med 4, Athens, Greece
Giamarellos-Bourboulis, EJ:
Natl & Kapodistrian Univ Athens, Med Sch, Dept Internal Med 4, Athens, Greece
Jemec, GBE:
Univ Copenhagen, Zealand Univ Hosp, Roskilde & Hlth Sci Fac, Dept Dermatol, Copenhagen, Denmark
Katoulis, AC:
Natl & Kapodistrian Univ Athens, Attikon Gen Univ Hosp, Med Sch, Dept Dermatol & Venereol 2, Athens, Greece
Koenig, A:
Univ Hosp Frankfurt Am Main, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
Lazaridou, E:
Aristotle Univ Thessaloniki, Gen Hosp Papageorgiou, Dept Dermatol & Venereol 2, Thessaloniki, Greece
Marzano, AV:
Fdn Ist Ricovero & Cura Carattere Sci CaGranda Os, Dermatol Unit, Milan, Italy
Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy
Matusiak, L:
Med Univ, Dept Dermatol Venereol & Allergol, Wroclaw, Poland
Molina-Leyva, A:
Hosp Univ Virgen Nieves, Dept Dermatol, Granada, Spain
TECe19 Clin & Translat Dermatol Invest Grp Inst I, Granada, Spain
Moltrasio, C:
Fdn Ist Ricovero & Cura Carattere Sci CaGranda Os, Dermatol Unit, Milan, Italy
Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy
Pinter, A:
Univ Hosp Frankfurt Am Main, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
Potenza, C:
Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Dermatol Unit Daniele Innocenzi, Polo Pontino Latina, Rome, Italy
Romani, J:
Corp Sanitaria Parc Tauli, Dept Dermatol, Sabadell, Italy
Saunte, DM:
Med Univ, Dept Dermatol Venereol & Allergol, Wroclaw, Poland
Skroza, N:
Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Dermatol Unit Daniele Innocenzi, Polo Pontino Latina, Rome, Italy
Stergianou, D:
Natl & Kapodistrian Univ Athens, Med Sch, Dept Internal Med 4, Athens, Greece
Szepietowski, J:
Med Univ, Dept Dermatol Venereol & Allergol, Wroclaw, Poland
Trigoni, A:
Aristotle Univ Thessaloniki, Gen Hosp Papageorgiou, Dept Dermatol & Venereol 2, Thessaloniki, Greece
Vilarrasa, E:
Univ Autonoma Barcelona, Dept Dermatol, Hosp Santa Creu & St Pau, Barcelona, Spain
van der Zee, HH:
Univ Med Ctr Rotterdam, Dept Dermatol, Erasmus MC, Rotterdam, Netherlands
hybrid, Green Published
|